Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Connect Biopharma Holdings Ltd
Note Receivable
Connect Biopharma Holdings Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
Note Receivable
¥108k
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Note Receivable
¥82.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Connect Biopharma Holdings Ltd
Glance View
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
See Also
What is Connect Biopharma Holdings Ltd's Note Receivable?
Note Receivable
108k
CNY
Based on the financial report for Dec 31, 2024, Connect Biopharma Holdings Ltd's Note Receivable amounts to 108k CNY.
What is Connect Biopharma Holdings Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
-56%
Over the last year, the Note Receivable growth was 0%. The average annual Note Receivable growth rates for Connect Biopharma Holdings Ltd have been -82% over the past three years , -56% over the past five years .
